IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Ltd is a leading pharmaceutical (APIs) company and is a significant player in the specialty chemicals space. It serves the domestic and export market.[1]
It is the largest player of Ibuprofen (pain killer) globally with a world market share of 35%.[2]
- Market Cap ₹ 5,614 Cr.
- Current Price ₹ 191
- High / Low ₹ 224 / 67.1
- Stock P/E 26.5
- Book Value ₹ 65.6
- Dividend Yield 0.52 %
- ROCE 11.3 %
- ROE 8.41 %
- Face Value ₹ 2.00
Pros
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 22.1%
Cons
- Stock is trading at 2.95 times its book value
- Company has a low return on equity of 7.72% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE 1000
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 385 | 580 | 711 | 983 | 1,685 | 1,894 | 1,967 | 2,184 | 2,217 | 2,133 | 2,079 | 2,319 | 2,751 | |
| Sales growth | -32% | +51% | +22% | +38% | +71% | +12% | +4% | +2% | -4% | -3% | +12% | +27% | |
| 373 | 529 | 608 | 863 | 1,276 | 1,321 | 1,375 | 1,925 | 1,991 | 1,902 | 1,877 | 2,049 | 2,388 | |
| Operating Profit | 11 | 51 | 102 | 120 | 410 | 574 | 592 | 259 | 226 | 231 | 202 | 270 | 363 |
| OPM % | 2.9% | 9% | 14% | 12% | 24% | 30% | 30% | 12% | 10% | 11% | 10% | 12% | 13% |
| 1 | 1 | 1 | 6 | 10 | 16 | 24 | 17 | 25 | 30 | 22 | 9 | 10 | |
| Interest | 59 | 61 | 68 | 64 | 51 | 21 | 6 | 8 | 16 | 16 | 15 | 15 | 16 |
| Depreciation | 29 | 30 | 30 | 30 | 32 | 36 | 39 | 43 | 46 | 63 | 72 | 80 | 84 |
| Profit before tax | -75 | -39 | 6 | 31 | 336 | 533 | 571 | 225 | 189 | 182 | 138 | 184 | 272 |
| Tax % | -12% | 4% | 21% | 12% | 30% | 32% | 22% | 25% | 26% | 26% | 27% | 25% | |
| -67 | -40 | 5 | 28 | 237 | 361 | 445 | 168 | 139 | 134 | 101 | 138 | 203 | |
| EPS in Rs | -2.80 | -1.42 | 0.17 | 0.99 | 8.32 | 12.70 | 15.15 | 5.71 | 4.74 | 4.58 | 3.44 | 4.69 | 6.92 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 5% | 8% | 14% | 17% | 22% | 23% | 21% |
(S): Standalone figures, shown where consolidated figures are not available.
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 2% |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 2% |
| TTM: | 83% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 26% |
| 5 Years: | 15% |
| 3 Years: | 32% |
| 1 Year: | 102% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 9% |
| 3 Years: | 8% |
| Last Year: | 8% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 56 | 56 | 56 | 57 | 57 | 59 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves | 160 | 129 | 132 | 160 | 417 | 757 | 1,202 | 1,334 | 1,449 | 1,553 | 1,629 | 1,740 | 1,867 |
| 400 | 453 | 447 | 422 | 284 | 59 | 3 | 44 | 80 | 33 | 117 | 135 | 201 | |
| 94 | 135 | 182 | 214 | 184 | 297 | 347 | 526 | 435 | 600 | 577 | 653 | 704 | |
| Total Liabilities | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,962 | 2,022 | 2,244 | 2,382 | 2,587 | 2,831 |
| 403 | 400 | 374 | 406 | 412 | 469 | 512 | 561 | 752 | 933 | 1,171 | 1,182 | 1,191 | |
| CWIP | 4 | 4 | 21 | 7 | 27 | 19 | 48 | 105 | 90 | 101 | 22 | 96 | 189 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 20 | 20 | 21 | 21 | 21 |
| 295 | 369 | 422 | 439 | 503 | 682 | 1,048 | 1,294 | 1,161 | 1,190 | 1,169 | 1,289 | 1,429 | |
| Total Assets | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,962 | 2,022 | 2,244 | 2,382 | 2,587 | 2,831 |
(S): Standalone figures, shown where consolidated figures are not available.
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -47 | 18 | 83 | 120 | 273 | 471 | 380 | 93 | 122 | 290 | 179 | 214 | |
| -5 | -27 | -23 | -50 | -63 | -184 | -317 | -121 | -120 | -191 | -154 | -198 | |
| 50 | 9 | -60 | -70 | -197 | -272 | -58 | -2 | -4 | -92 | 46 | -29 | |
| Net Cash Flow | -2 | -0 | 1 | -1 | 13 | 15 | 4 | -29 | -2 | 6 | 70 | -13 |
| Free Cash Flow | -53 | -9 | 61 | 71 | 213 | 391 | 272 | -58 | -87 | 17 | -34 | 43 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -413% | 34% | 82% | 105% | 83% | 102% | 88% | 60% | 75% | 144% | 97% | 93% |
(S): Standalone figures, shown where consolidated figures are not available.
Ratios
Consolidated / View Standalone
| Mar 2015 (S) | Mar 2016 (S) | Mar 2017 (S) | Mar 2018 (S) | Mar 2019 (S) | Mar 2020 (S) | Mar 2021 (S) | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 31 | 55 | 58 | 54 | 43 | 52 | 56 | 79 | 83 | 81 | 90 | 95 |
| Inventory Days | 279 | 201 | 201 | 109 | 66 | 64 | 98 | 95 | 77 | 111 | 95 | 91 |
| Days Payable | 92 | 102 | 115 | 83 | 42 | 62 | 79 | 95 | 74 | 123 | 112 | 118 |
| Cash Conversion Cycle | 218 | 154 | 144 | 80 | 67 | 55 | 74 | 79 | 86 | 69 | 73 | 68 |
| Working Capital Days | 59 | 39 | 36 | 23 | 43 | 46 | 66 | 71 | 72 | 71 | 58 | 53 |
| ROCE % | -3% | 4% | 12% | 15% | 56% | 68% | 54% | 14% | 12% | 9% | 11% |
(S): Standalone figures, shown where consolidated figures are not available.
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Export Revenue Share % of total sales ・Standalone data |
|
||||||||||
| Installed Capacity - Ibuprofen MTPA ・Standalone data |
|||||||||||
| Installed Capacity - Ethyl Acetate MTPA ・Standalone data |
|||||||||||
| Installed Capacity - Paracetamol MTPA ・Standalone data |
|||||||||||
| Non-Ibuprofen Share in Pharma Revenue % of pharma segment revenue ・Standalone data |
|||||||||||
| Capacity Utilisation - Chemicals % ・Standalone data |
|||||||||||
| Capacity Utilisation - Pharmaceuticals % ・Standalone data |
|||||||||||
| Regulatory Approvals (CEPs and DMFs) count ・Standalone data |
|||||||||||
| R&D Expenditure (Percentage of Turnover) % ・Standalone data |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Clarification On Increase In Volume
- Company clarified no undisclosed event behind recent trading volume increase.
-
Clarification sought from IOL Chemicals & Pharmaceuticals Ltd
- Exchange has sought clarification from IOL Chemicals & Pharmaceuticals Ltd on November 11, 2026, with reference to Movement in Volume.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Transcript of Earning Call on the Q2 & H1 FY27 Financial Results
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Audio recording released for Q2 and H1 FY27 earnings call held on 2 November 2026.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor Presentation- Q2 & H1 FY27
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
Nov 2026Transcript PPT REC
-
Sep 2026Transcript REC
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT
-
Nov 2025Transcript PPT
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT REC
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
May 2023PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021Transcript PPT
-
Dec 2020Transcript PPT
-
Nov 2020PPT
Business Segment
a) Pharmaceuticals Segment [1]
Product Portfolio: Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Paracetamol, Clopidogrel, Pantoprazole Sodium, Fenofibrate, Levetiracetam, Lamotrigine, Losartan Potassium